8-Prenylnaringenin — 8-PN (Prenylflavonoid · Most Potent Dietary Phytoestrogen · Menopausal Support)

Compound	8-Prenylnaringenin (8-PN)
Chemical class	Polyphenol — Prenylflavonoid (Prenylated Flavanone)
CAS	53846-50-7
Primary source	Humulus lupulus (hops strobiles); gut microbial metabolite of xanthohumol
Key applications	Most potent known dietary phytoestrogen, menopausal support
Claim strength	Moderate
Typical form	Hops extract co-constituent; isolated 8-PN (specialist supply)
Buy from Herbuno	Hops Flower Extract Powder - Humulus lupulus →

Name origin: 8-Prenylnaringenin = naringenin (the flavanone) with a prenyl (3-methylbut-2-enyl) group attached at C-8 of the A-ring. The numbering specifies the prenyl position distinguishing it from 6-prenylnaringenin and other positional isomers. Also called 8-PN. Traditional use: Historically, hop pickers in England reported disruption to their menstrual cycles during the harvest season — a phenomenon now attributed to 8-PN dermal and occupational exposure during intensive contact with hop strobiles. This observation is considered one of the first documented phytoestrogenic effects. 8-PN is a natural constituent of hops and a gut microbial metabolite of xanthohumol. Research trajectory: 8-PN is recognised as the most potent known dietary phytoestrogen, with ER binding affinity approximately 0.1–10% of oestradiol — far exceeding genistein, daidzein, and coumestrol. Multiple human RCTs have studied 8-PN-standardised hops extract for menopausal hot flush reduction. Commercial source: 8-Prenylnaringenin is commercially available as a co-constituent of hops (Humulus lupulus) flower extract; isolated 8-PN is available from specialist suppliers at research and premium supplement scale. See sourcing options below.

---

Evidence for 8-PN Applications

Menopausal hot flush reduction: Multiple European RCTs (primarily German and Belgian studies) using hops extract standardised to 8-PN content demonstrate significant reduction in hot flush frequency and severity in postmenopausal women over 12–16 weeks. A well-designed double-blind crossover study showed 8-PN-standardised hops extract significantly superior to placebo for hot flush relief. Dose-dependent effects are observed in the 100–250 µg/day 8-PN range. Claim strength: Moderate.

Bone density and estrogenic target tissue effects: 8-PN’s high ER affinity predicts bone-protective activity; animal studies in ovariectomised models confirm preservation of trabecular bone density. Human bone density data are limited to secondary endpoints in menopausal RCTs showing trends toward BMD preservation. Claim strength: Moderate.

Vaginal and urogenital effects: Clinical studies report improvement in vaginal dryness and urogenital atrophy symptoms with 8-PN-standardised hops extract — effects consistent with estrogenic activity at urogenital ERα targets. Claim strength: Moderate.

---

Dosage & Formulator Specification

Clinical RCTs: 100–250 µg/day 8-PN (as isolated or standardised hops extract) demonstrated significant menopausal symptom relief. This is an exceptionally low absolute dose reflecting 8-PN’s very high estrogenic potency. Hops extract must be standardised to 8-PN content (HPLC-verified) to achieve reliable dosing — total hops extract weight is not a sufficient specification.

Standard hops extracts contain 0.006–0.10% 8-PN by weight depending on variety and processing. To deliver 200 µg/day 8-PN, approximately 200–3,300 mg/day hops extract is required depending on 8-PN concentration — this wide range underscores the necessity of 8-PN-specific standardisation. Herbuno’s hops extract 8-PN content should be confirmed by HPLC prior to dose calculation.

8-PN is lipophilic with low aqueous solubility. Microencapsulation or cyclodextrin complexation is used in commercial menopausal supplement formulations to improve dissolution and bioavailability. Given the very low active dose (µg level), precise HPLC-verified dosing is critical for both efficacy and safety.

---

Frequently Asked Questions — 8-Prenylnaringenin

How potent is 8-PN as a phytoestrogen compared to oestradiol?
8-PN has ERα and ERβ binding affinity approximately 0.1–10% of oestradiol in receptor competition assays — the highest recorded for any dietary phytoestrogen. For comparison, genistein’s ERβ affinity is approximately 0.1–1% of oestradiol, and coumestrol is 0.1–5%. 8-PN’s potency means effective doses are in the microgram rather than milligram range, a significant practical formulation differentiator.

Should 8-PN supplement products carry specific hormone-sensitive safety advisories?
Yes. Given 8-PN’s high estrogenic potency, products standardised to 8-PN content should carry clear advisory language for individuals with hormone-sensitive conditions (oestrogen-receptor positive cancers, endometriosis, uterine fibroids) and for premenopausal women not seeking estrogenic effects. The level of advisory language should be proportional to the 8-PN dose in the product.

Is 8-PN from hops a viable alternative to HRT for mild menopausal symptoms?
For mild-to-moderate hot flush relief in women who prefer non-pharmaceutical phytoestrogenic options, 8-PN-standardised hops extract has moderate RCT support and is a clinically rational choice. It is not equivalent to or a replacement for pharmaceutical HRT in terms of efficacy for severe symptoms, fracture prevention, or cardiovascular menopausal indications. Position as a complement to, or preference-based alternative for, mild symptom management.

What is the regulatory status of 8-PN in menopausal supplements?
8-PN does not have an EU or US approved health claim. In the EU, hops extract appears on the list of botanicals with established traditional use; specific 8-PN health claims require substantiation under EFSA’s Article 13 process. In the US, hops-based products containing 8-PN are marketed as dietary supplements without structure/function approval for specific estrogenic claims. Menopausal symptom relief claims require careful regulatory navigation in most markets.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery